What Happened?

Shares of healthcare services company Agilon Health (NYSE:AGL) fell 24.9% in the afternoon session after the company reported weak first quarter 2025 results as new customer additions fell short.

On the other hand, revenue and EBITDA for the full-year exceeded Wall Street's estimates. That said, with Medicare Advantage members down 6%, growth is clearly cooling. Zooming out, we think this was a decent quarter featuring some areas of strength but also some blemishes.

The shares closed the day at $3.36, down 25.2% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy agilon health? Access our full analysis report here, it’s free.

What The Market Is Telling Us

agilon health’s shares are extremely volatile and have had 78 moves greater than 5% over the last year. But moves this big are rare even for agilon health and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 29 days ago when the stock gained 29.9% on the news that Bernstein upgraded the stock's rating from Hold to Buy with a price target of $8.5. The firm noted that new data on AGL drove increased confidence in its turnaround plans and cash position.

agilon health is up 76% since the beginning of the year, but at $3.38 per share, it is still trading 55.1% below its 52-week high of $7.52 from July 2024. Investors who bought $1,000 worth of agilon health’s shares at the IPO in April 2021 would now be looking at an investment worth $109.03.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

View Comments